Replimune Group (NASDAQ:REPL) Receives "Buy" Rating from HC Wainwright

HC Wainwright restated their buy rating on shares of Replimune Group (NASDAQ:REPL - Free Report) in a research note published on Friday,Benzinga reports. The firm currently has a $17.00 price target on the stock.

A number of other brokerages have also issued reports on REPL. JPMorgan Chase & Co. upped their price objective on shares of Replimune Group from $14.00 to $17.00 and gave the company an "overweight" rating in a report on Tuesday, September 24th. Roth Capital raised Replimune Group to a "strong-buy" rating in a research report on Tuesday, August 27th. Finally, Roth Mkm began coverage on shares of Replimune Group in a research note on Tuesday, August 27th. They issued a "buy" rating and a $17.00 price target for the company. Six research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of "Buy" and a consensus target price of $17.00.

Replimune Group Price Performance

Shares of NASDAQ REPL traded up $3.88 during trading on Friday, hitting $14.93. The company had a trading volume of 5,992,027 shares, compared to its average volume of 1,053,894. The firm has a market capitalization of $1.02 billion, a price-to-earnings ratio of -5.20 and a beta of 1.19. The stock has a fifty day simple moving average of $11.51 and a two-hundred day simple moving average of $9.67. The company has a quick ratio of 10.11, a current ratio of 10.11 and a debt-to-equity ratio of 0.18. Replimune Group has a fifty-two week low of $4.92 and a fifty-two week high of $17.00.

Replimune Group (NASDAQ:REPL - Get Free Report) last released its earnings results on Tuesday, November 12th. The company reported ($0.68) earnings per share for the quarter, topping analysts' consensus estimates of ($0.75) by $0.07. On average, research analysts expect that Replimune Group will post -3.02 earnings per share for the current year.

Insider Buying and Selling

In related news, insider Konstantinos Xynos sold 7,246 shares of the firm's stock in a transaction dated Monday, November 18th. The stock was sold at an average price of $10.78, for a total transaction of $78,111.88. Following the transaction, the insider now owns 109,885 shares of the company's stock, valued at $1,184,560.30. This trade represents a 6.19 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. 8.80% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of REPL. Nisa Investment Advisors LLC grew its position in Replimune Group by 10,304.2% in the 2nd quarter. Nisa Investment Advisors LLC now owns 4,994 shares of the company's stock valued at $45,000 after buying an additional 4,946 shares during the last quarter. Point72 DIFC Ltd acquired a new stake in shares of Replimune Group in the 2nd quarter valued at approximately $57,000. Arizona State Retirement System acquired a new position in Replimune Group during the second quarter worth $108,000. Quest Partners LLC lifted its holdings in Replimune Group by 30.4% in the second quarter. Quest Partners LLC now owns 13,510 shares of the company's stock valued at $122,000 after acquiring an additional 3,150 shares during the period. Finally, Erste Asset Management GmbH acquired a new position in shares of Replimune Group during the 3rd quarter worth $133,000. Institutional investors and hedge funds own 92.53% of the company's stock.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.